Cellosaurus HEY (CVCL_0297)

Cell line name HEY
Synonyms Hey
Accession CVCL_0297
Resource Identification Initiative To cite this cell line use: HEY (RRID:CVCL_0297)
Comments Part of: MD Anderson Cell Lines Project.
Doubling time: 30 hours (PubMed=4016745).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_4995 (HX/62)
Children: CVCL_L041 (HEY A4); CVCL_8878 (HEY A8); CVCL_L040 (HEY AS1); CVCL_X009 (HEY C2); CVCL_AZ64 (HEY-1B); CVCL_2Z96 (HEY-T30); CVCL_JZ11 (HEY/GFP)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11
D13S31711
D16S5398,12
D18S5115
D21S1130
D3S135816
D5S81811,12
D7S82012
D8S117913
FGA20,21
Penta D9,13
Penta E7,13
TH018,9.3
TPOX11
vWA16,17
Web pages https://www.cedarlanelabs.com/Products/Detail/CLU302?lob=Cellutions
http://tcpaportal.org/mclp/
Publications

PubMed=4016745
Buick R.N., Pullano R., Trent J.M.
Comparative properties of five human ovarian adenocarcinoma cell lines.
Cancer Res. 45:3668-3676(1985)

PubMed=3731068
Baumal R., Law J., Buick R.N., Kahn H., Yeger H., Sheldon K., Colgan T., Marks A.
Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line.
Cancer Res. 46:3994-4000(1986)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line databases/resources Cosmic-CLP; 1479988
GDSC; 1479988
Ontologies BTO; BTO:0002590
EFO; EFO_0006580
MCCL; MCC:0000188
Biological sample resources BioSample; SAMN03473280
Chemistry resources ChEMBL-Cells; CHEMBL3308082
ChEMBL-Targets; CHEMBL613869
Gene expression databases GEO; GSM659377
GEO; GSM1669880
Polymorphism and mutation databases Cosmic; 1102812
Cosmic; 1524358